MedTrace Logo

Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)

NCT01730170 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 565

Last updated 2023-07-13

No results posted yet for this study

Summary

Epilepsy is one of the most common neurological disorders affecting women of childbearing age. Poor pregnancy outcomes are increased in these women and their children. The proposed studies will increase our knowledge on multiple levels to improve care and reduce adverse outcomes in these mothers and children. An overall goal of this study is to establish the relationship between antiepileptic drug exposure and outcomes in the mother and child as well as describe and explain the variability in antiepileptic drug exposure and response.

Conditions

Sponsors & Collaborators

  • The Emmes Company, LLC

    collaborator INDUSTRY

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Kimford J Meador, M.D. · Stanford University

  • Page B Pennell, M.D. · University of Pittsburgh

  • Abigail Matthews, PhD · The Emmes Company, LLC

Eligibility

Min Age
14 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2022-12-12
Completion
2022-12-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01730170 on ClinicalTrials.gov